Antigen dose escalation study of a VEGF-based therapeutic cancer vaccine in non human primates (Q62566469)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22075086%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

title

Antigen dose escalation study of a VEGF-based therapeutic cancer vaccine in non human primates (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22075086%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

0 references

1 reference

primates

1 reference

Yanelys Morera

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22075086%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

Mónica Bequet-Romero

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22075086%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

Marta Ayala

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22075086%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

Pedro Puente Pérez

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22075086%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

Jorge Castro

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22075086%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

Javier Sánchez

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22075086%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

José Suárez Alba

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22075086%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

Julio Ancízar

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22075086%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

Karelia Cosme

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22075086%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

Jorge V Gavilondo

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22075086%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

language of work or name

English

0 references

publication date

7 November 2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22075086%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

number of pages

10

1 reference

based on heuristic

inferred from page(s)

published in

Vaccine

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22075086%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

volume

30

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22075086%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22075086%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

page(s)

368-377

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22075086%20AND%20SRC:MED&resulttype=core&format=json

Vaccines targeting the neovasculature of tumors

16 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.10.082

Vaccines targeting tumour angiogenesis--a novel strategy for cancer immunotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.10.082

Immunotherapy of tumors with vaccines based on xenogeneic homologous molecules

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.10.082

Phase I clinical trial using peptide vaccine for human vascular endothelial growth factor receptor 2 in combination with gemcitabine for patients with advanced pancreatic cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.10.082

Gastrointestinal bleeding during anti-angiogenic peptide vaccination in combination with gemcitabine for advanced pancreatic cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.10.082

Pilot study of anti-angiogenic vaccine using fixed whole endothelium in patients with progressive malignancy after failure of conventional therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.10.082

Very small size proteoliposomes derived from Neisseria meningitidis: An effective adjuvant for generation of CTL responses to peptide and protein antigens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.10.082

Anti-tumoral effect of active immunotherapy in C57BL/6 mice using a recombinant human VEGF protein as antigen and three chemically unrelated adjuvants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.10.082

Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.10.082

Small molecules and targeted therapies in distant metastatic disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.10.082

Adverse effects of anticancer agents that target the VEGF pathway

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.10.082

Immunogenicity and some safety features of a VEGF-based cancer therapeutic vaccine in rats, rabbits and non-human primates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.10.082

Inhibition of tumor-induced myeloid-derived suppressor cell function by a nanoparticulated adjuvant

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.10.082

A novel cancer vaccine composed of human-recombinant epidermal growth factor linked to a carrier protein: report of a pilot clinical trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.10.082

Heterologous prime-boost immunization in rhesus macaques by two, optimally spaced particle-mediated epidermal deliveries of Plasmodium falciparum circumsporozoite protein-encoding DNA, followed by intramuscular RTS,S/AS02A.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.10.082

Physiological and pathological roles of a multi-ligand receptor CD36 in atherogenesis; insights from CD36-deficient patients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.10.082

Carboxyfluorescein diacetate succinimidyl ester fluorescent dye for cell labeling

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.10.082

Use of Epstein-Barr virus-transformed, autologous B-lymphoblastoid cells as antigen-presenting cells for establishment and maintenance of dengue virus-specific, human cytotoxic T lymphocyte clones

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.10.082

A novel assay for assessment of HIV-specific cytotoxicity by multiparameter flow cytometry

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.10.082

Methylglyoxal administration induces diabetes-like microvascular changes and perturbs the healing process of cutaneous wounds.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.10.082

Targeted Therapies: Bevacizumab and interferon-alpha in metastatic renal-cell carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.10.082

FDA drug approval summary: bevacizumab (Avastin) as treatment of recurrent glioblastoma multiforme

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.10.082

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.10.082

Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.10.082

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.10.082

Bevacizumab vs ranibizumab for age-related macular degeneration: 1-year outcomes of a prospective, double-masked randomised clinical trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.10.082

Active specific immunotherapy of melanoma with a GM3 ganglioside-based vaccine: a report on safety and immunogenicity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.10.082

Epitope spreading in immune-mediated diseases: implications for immunotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.10.082

Therapeutic vaccination with epidermal growth factor (EGF) in advanced lung cancer: analysis of pooled data from three clinical trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.10.082

Autoimmunity, microbial immunity and the immunological homunculus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.10.082

Durable carcinoembryonic antigen (CEA)-specific humoral and cellular immune responses in colorectal carcinoma patients vaccinated with recombinant CEA and granulocyte/macrophage colony-stimulating factor.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.10.082

Bevacizumab and ranibizumab on microvascular endothelial cells: A comparative study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.10.082

Active immunization against the vascular endothelial growth factor receptor flk1 inhibits tumor angiogenesis and metastasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.10.082

Immunotherapy of tumors with vaccine based on quail homologous vascular endothelial growth factor receptor-2

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.10.082

Immunogene therapy of tumors with vaccine based on Xenopus homologous vascular endothelial growth factor as a model antigen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.10.082

VEGF kinoid vaccine, a therapeutic approach against tumor angiogenesis and metastases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.10.082

Prophylactic naked DNA vaccination with the human vascular endothelial growth factor induces an anti-tumor response in C57Bl/6 mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.10.082

Evaluation of a xenogeneic VEGF vaccine in dogs with soft tissue sarcoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.10.082

10.1016/J.VACCINE.2011.10.082

7 January 2021

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22075086%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

1 reference